This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock

Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.

Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Biotech columnist Adam Feuerstein answers readers' questions about health care.

MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.

Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.

Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

Sarepta Submits DMD Drug for FDA Approval Review

New Sarepta CEO Ed Kaye filed for approval of eteplirsen with the FDA as promised, allowing him to check off a hugely important item on the company's to-do list.

Biotech Stock Mailbag: Exelixis, Puma Bio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Alcobra Placebo Beats Drug in Failed Genetic Disease Study

Alcobra's MDX has now failed to demonstrate benefit for patients in two different clinical trials.

Page 4 of 340
Top Rated Stocks Top Rated Funds Top Rated ETFs